Abcam, ab251405, Anti-AKR1C1+AKR1C2+AKR1C3 antibody [EPR16725] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal AKR1C3 antibody. Carrier free. Suitable for IP, WB and reacts with Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR16725,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:IP, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab251405 is the carrier-free version of
ab203834
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The AKR1C3 AKR1C2 and AKR1C1 proteins collectively known as aldo-keto reductase family 1 members C3 C2 and C1 are enzymes that convert carbonyl groups into alcohols in various biological processes. AKR1C3 also called 17β-hydroxysteroid dehydrogenase type 5 has a mass of approximately 37 kDa. These proteins are found in several tissues including liver prostate and mammary glands. They play a role in steroid hormone metabolism and are essential in regulating androgen progesterone and prostaglandin levels.
Biological function summary
The AKR1C3 enzyme modifies steroid hormones impacting cell proliferation and differentiation. AKR1C2 and AKR1C1 have similar functions but can affect other substances such as bile acids and xenobiotics. Together they do not form a single complex but act in overlapping and multiple pathways collectively influencing hormone levels and metabolic processes. Their activity affects the balance of active and inactive forms of various hormones contributing to normal cellular function.
Pathways
AKR1C3 AKR1C2 and AKR1C1 participate in steroid hormone biosynthesis and retinoic acid metabolism. They interrelate with enzymes like cytochrome P450 in the synthesis and breakdown of hormones and retinoids. This association affects cellular signaling and gene expression particularly in response to hormone fluctuations. Their integration into these pathways highlights their contribution to homeostasis and the intricate regulation of biochemical processes.
These proteins have connections to prostate cancer and breast cancer. Their role in androgen and estrogen metabolism influences tumor growth and progression. In prostate cancer AKR1C3 interacts with androgen receptor signaling intensifying the disease state. For breast cancer it affects estrogen receptor pathways where altered expression may lead to hormone-resistant forms of cancer. Understanding these associations aids in identifying therapeutic targets for these conditions.